专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018055535A2 HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
标题翻译：丙型肝炎病毒免疫原性组合物及其使用方法
公开(公告)号：WO2018055535A2
公开(公告)日：2018-03-29
申请号：PCT/IB2017/055714
申请日：2017-09-21
申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
发明人： HOUGHTON, Michael , LANDI, Abdolamir , LOGAN, Michael , LAW, John L. , HOCKMAN, Darren , CHEN, Chao
IPC分类号： A61K39/29
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/53 , A61K2039/54 , A61K2039/55544 , A61K2039/70 , C12N2710/10034 , C12N2710/10043 , C12N2710/24134 , C12N2710/24143 , C12N2770/24234
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
摘要翻译：本公开内容提供了免疫原性组合物，其包含：a）包含HCV E1和E2多肽的丙型肝炎病毒（HCV）异源二聚体多肽; b）包含存在于E1和E2以外的HCV蛋白中的T细胞表位的T细胞表位多肽; 和c）药学上可接受的赋形剂。本公开内容提供了在个体中诱导HCV多肽的免疫应答的方法。本公开内容提供了免疫原性组合物，其包含：a）包含存在于除E1和E2以外的HCV蛋白质中的一个或多个T细胞表位的多肽; 和b）药学上可接受的赋形剂。

2. 发明申请

WO2017060857A1 HEPATITIS C VIRUS E1/E2 HETERODIMERS AND METHODS OF PRODUCING SAME 审中-公开
标题翻译： HEPATITIS C VIRUS E1 / E2 HETERODIMERS及其生产方法
公开(公告)号：WO2017060857A1
公开(公告)日：2017-04-13
申请号：PCT/IB2016/056000
申请日：2016-10-07
申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
发明人： HOUGHTON, Michael , HOCKMAN, Darren , LAW, John L. , CHEN, Chao , LOGAN, Michael
IPC分类号： C07K19/00 , A61K39/385 , A61P31/14 , A61P37/04 , C07K1/22 , C07K14/18 , C07K16/00 , C07K7/06 , C12N15/51 , C12N15/62 , C12P21/02
CPC分类号： A61K39/385 , A61K39/12 , A61K2039/54 , A61K2039/55505 , A61K2039/55572 , A61K2039/575 , C07K1/22 , C07K14/005 , C07K19/00 , C07K2319/30 , C07K2319/50 , C12N15/62 , C12N2770/24222 , C12N2770/24234 , C12P21/02
摘要： The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) El polypeptide and an HCV E2 polypeptide, where one or both of the El and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.
摘要翻译：本公开提供包含丙型肝炎病毒（HCV）E1多肽和HCV E2多肽的亲和标记的异二聚体多肽，其中E1和E2多肽中的一个或两个包含亲和标签。本公开提供了产生本公开的亲和标记的E1 / E2异源二聚体的方法。本公开提供了生产未标记的HCV E1 / E2异源二聚体的方法。本公开提供HCV E1 / E2异源二聚体，包含其的组合物和诱导对HCV的免疫应答的方法。

3. 发明申请

WO2017006182A1 HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
标题翻译： HEPATITIS C病毒免疫组合物及其使用方法
公开(公告)号：WO2017006182A1
公开(公告)日：2017-01-12
申请号：PCT/IB2016/001051
申请日：2016-07-06
申请人： THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
发明人： HOUGHTON, Michael , LAW, John, L. , LOGAN, Michael , HOCKMAN, Darren , LANDI, Abdolamir
IPC分类号： C07K19/00 , A61K39/295 , A61P31/04 , A61P31/14 , A61P37/04 , C07K1/14
CPC分类号： A61K39/29 , A61K39/12 , A61K39/295 , A61K2039/55544 , A61P31/04 , A61P31/14 , A61P37/04 , C07K2319/00 , C12N15/861 , C12N2770/24234
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV El polypeptide; 2) a variant HCV El polypeptide and an HCV E2 polypeptide; or 3) a variant HCV El polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV El polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV El polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes El and variant E2, E2 and variant El, or variant E2 and variant El. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
摘要翻译：本公开提供异二聚体多肽，其包含：1）变体丙型肝炎病毒（HCV）E2多肽和HCV E1多肽; 2）变体HCV E1多肽和HCV E2多肽; 或3）变体HCV E1多肽和变体HCV E2多肽，其中变体HCV E2多肽和/或HCV E1多肽包含存在于除HCV E1多肽或HCV之外的HCV多肽中的一种或多种T细胞表位 E2多肽。本公开提供编码多蛋白的核酸，其包括E1和变体E2，E2和变体E1，或变体E2和变体E1。本公开提供了制备本发明的E1 / E2异源二聚体的方法。本公开提供了在个体中诱导免疫应答的方法。本公开提供变体E2多肽和变体E1多肽; 和编码相同的核酸。

4. 发明申请

WO2016049769A1 ANIMAL MODELS, CELL LINES AND METHODS FOR SCREENING HEPATITIS C VIRUS VACCINES 审中-公开
标题翻译：动物模型，细胞系和筛选乙型肝炎疫苗的方法
公开(公告)号：WO2016049769A1
公开(公告)日：2016-04-07
申请号：PCT/CA2015/050989
申请日：2015-10-01
申请人： NATIONAL RESEARCH COUNCIL OF CANADA
发明人： YOUNG, Kevin , KRISHNAN, Lakshmi
IPC分类号： C12N15/85 , A01K67/027 , C12N15/51 , C12N5/10 , C12Q1/00 , C12Q1/02 , C12Q1/68 , C12Q1/70
CPC分类号： A01K67/0271 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , A01K2267/0337 , A01K2267/0393 , A61K39/12 , A61K2039/523 , A61K2039/5256 , C12N5/0693 , C12N7/00 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2840/206 , C12Q1/707
摘要： Modified non-human mammalian hepatoma cell lines that express hepatitis C virus (HCV) antigens and which are capable of generating tumours in a syngeneic animal model are provided. The cell lines are generated by genomic integration of an expression construct that comprises one or more HCV antigen-encoding sequences under the control of a constitutive promoter. The expression construct further comprises a selectable marker and a reporter gene under the control of the same promoter. The cell lines are useful for testing prophylactic and therapeutic vaccines against HCV either in vitro or in vivo.
摘要翻译：提供了表达丙型肝炎病毒（HCV）抗原并且能够在同基因动物模型中产生肿瘤的修饰的非人哺乳动物肝癌细胞系。通过在组成型启动子控制下包含一个或多个HCV抗原编码序列的表达构建体的基因组整合产生细胞系。表达构建体还包含在相同启动子控制下的选择标记和报告基因。细胞系可用于在体外或体内测试针对HCV的预防性和治疗性疫苗。

5. 发明申请

WO2015128731A3 COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C 审中-公开
公开(公告)号：WO2015128731A3
公开(公告)日：2015-12-17
申请号：PCT/IB2015000397
申请日：2015-02-24
申请人： VARIATION BIOTECHNOLOGIES INC
发明人： ANDERSON DAVID E
IPC分类号： C12N15/85 , A61K35/76 , A61K39/21 , A61K39/29 , A61K39/295 , A61P31/14 , C07K14/145 , C07K14/18 , C07K19/00 , C12N7/01 , C12N7/04 , C12N15/62
CPC分类号： C07K14/15 , A61K39/29 , A61K2039/5258 , C07K14/005 , C07K14/1833 , C07K2319/40 , C12N7/045 , C12N2740/13023 , C12N2740/13041 , C12N2770/24234
摘要： The present disclosure provides compositions and methods useful for treating HCV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCV epitopes, such as, for example, from HCV envelope glycoprotein El and/or E2 or variants thereof (e.g., E2G) and/or non-structural proteins NS3 and/or NS4A. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and interior non-structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).

6. 发明申请

WO2015104656A1 IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
标题翻译：免疫组化及其使用方法
公开(公告)号：WO2015104656A1
公开(公告)日：2015-07-16
申请号：PCT/IB2015/050108
申请日：2015-01-07
申请人： AGRAWAL, Babita , KUMAR, Rakesh
发明人： AGRAWAL, Babita , KUMAR, Rakesh
IPC分类号： A61K39/39 , A61K39/00 , A61P37/04
CPC分类号： A61K39/02 , A61K39/0011 , A61K39/015 , A61K39/04 , A61K39/12 , A61K39/35 , A61K39/39 , A61K39/395 , A61K2039/505 , A61K2039/521 , A61K2039/55516 , A61K2039/55572 , A61K2039/58 , C12N2710/10343 , C12N2730/10134 , C12N2760/16134 , C12N2760/16234 , C12N2770/24234 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/491
摘要： The present disclosure provides immunomodulatory compositions comprising heat-killed Caulobacter crescentus (HKCC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising HKCC to the individual.
摘要翻译：本公开提供了包含热灭活的新月牙菌（HKCC）的免疫调节组合物。本公开的免疫调节组合物可用于调节个体的免疫应答。本公开因此提供调节个体的免疫应答的方法，包括向个体施用包含HKC的免疫调节组合物。

7. 发明申请

WO2015058772A3 NOVEL HCV CULTURE SYSTEMS AND DIRECT-ACTING ANTIVIRAL SENSITIVITY 审中-公开
标题翻译：新型HCV文化系统和直接作用的抗病毒敏感性
公开(公告)号：WO2015058772A3
公开(公告)日：2015-06-18
申请号：PCT/DK2014050343
申请日：2014-10-21
申请人： HVIDOVRE HOSPITAL
发明人： LI YIPING , ALMEIDA SANTSEHARAY RAMIREZ , HUMES DARYL GRANT , GOTTWEIN JUDITH M , BUKH JENS
IPC分类号： C12N7/00 , A61K39/12 , C07K16/10 , G01N33/53
CPC分类号： C12N7/00 , C12N2770/24221 , C12N2770/24234 , C12N2770/24251 , C12N2770/24252 , C12Q1/025
摘要： The present invention relates to hepatitis C virus (HCV) culture systems of genotypes 1a, 3a, 4a, 5a, and 6a that directly contribute to HCV drug and vaccine development, to HCV basic research and better-individualized treatment of HCV infected patients.
摘要翻译：本发明涉及直接有助于HCV药物和疫苗开发的基因型1a，3a，4a，5a和6a的丙型肝炎病毒（HCV）培养系统，HCV基因研究和HCV感染患者的更好个体化治疗。

8. 发明申请

WO2014162031A1 VECTORES RECOMBINANTES BASADOS EN EL VIRUS MODIFICADO DE ANKARA (MVA) COMO VACUNAS PREVENTIVAS Y TERAPÉUTICAS CONTRA LA HEPATITIS C 审中-公开
标题翻译：基于修饰的疫苗病毒（MVA）的重组载体作为预防和治疗乙型肝炎病毒疫苗
公开(公告)号：WO2014162031A1
公开(公告)日：2014-10-09
申请号：PCT/ES2014/070246
申请日：2014-03-31
申请人： CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)
发明人： ESTEBAN RODRIGUEZ, Mariano , GÓMEZ RODRÍGUEZ, Carmen Elena , PERDIGUERO DE LA TORRE, Beatriz
IPC分类号： C12N15/863 , A61K39/29 , A61P31/14
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/53 , C12N2710/24143 , C12N2770/24234
摘要： Los virus recombinantes de la invención contienen secuencias que se encuentran insertadas en el mismo sitio de inserción del MVA y que permiten la expresión simultáneamente de varios antígenos del VHC, concretamente las proteínas maduras estructurales (Core, E1, E2 y p7) y no estructurales (NS2, NS3, NS4A, NS4B, NS5A más los 201 aminoácidos de la región N-terminal de NS5B). Con ello se consiguen virus recombinantes estables, que permiten el desencadenamiento de una respuesta inmune contra una gran variedad de antígenos del VHC, adecuados para ser utilizados como vacunas preventivas y terapéuticas contra la hepatitis C.
摘要翻译：本发明的重组病毒含有插入与MVA相同的插入位点的序列，并允许同时表达HCV的各种抗原，具体地，结构（核心，E1，E2和p7）和非结构（ NS2，NS3，NS4A，NS4B，NS5A加上NS5B N末端区域的201个氨基酸）成熟蛋白。以这种方式，获得稳定的重组病毒，其允许针对大量各种HCV抗原触发免疫应答，适合用作抗丙型肝炎的预防和治疗疫苗。

9. 发明申请

WO2014128568A2 COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C 审中-公开
标题翻译：用于治疗乙型肝炎的组合物和方法C
公开(公告)号：WO2014128568A2
公开(公告)日：2014-08-28
申请号：PCT/IB2014/000815
申请日：2014-02-25
申请人： VARIATION BIOTECHNOLOGIES, INC.
发明人： ANDERSON, David, E. , KLATZMANN, David
IPC分类号： C12N15/85
CPC分类号： C07K14/005 , A61K2039/5258 , C07K2319/03 , C12N2740/16222 , C12N2770/24222 , C12N2770/24234
摘要： The present disclosure provides compositions and methods useful for treating HCV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCV epitopes, such as, for example, from HCV envelope glycoprotein El and/or E2 or variants thereof (e.g., E2G) and/or non-structural proteins NS3 and/or NS4A. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and interior non-structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
摘要翻译：本公开提供了可用于治疗HCV感染的组合物和方法。如本文所述，组合物和方法基于免疫原性组合物的开发，所述免疫原性组合物包括包含一种或多种莫洛尼鼠白血病病毒（MMLV）核心蛋白的病毒样颗粒（VLP），并且包括一个或多个HCV表位，例如例如，来自HCV包膜糖蛋白E1和/或E2或其变体（例如E2G）和/或非结构蛋白NS3和/或NS4A。除其他之外，本发明包括认识到抗原（例如，包膜糖蛋白和内部非结构蛋白）的组合可导致有益的免疫应答，例如包括体液应答（例如产生中和抗体）和细胞反应（例如T细胞活化）。

10. 发明申请

WO2013139339A1 HCV FULL-LENGTH INFECTIOUS CELL CULTURE SYSTEMS AND APPLICATIONS THEREOF 审中-公开
标题翻译： HCV全长感染细胞培养系统及其应用
公开(公告)号：WO2013139339A1
公开(公告)日：2013-09-26
申请号：PCT/DK2013/050070
申请日：2013-03-15
申请人： HVIDOVRE HOSPITAL , KØBENHAVNS UNIVERSITET
发明人： LI, Yiping , SCHEEL, Troels Kasper Høyer , ALMEIDA, Santseharay Ramirez , GOTTWEIN, Judith M. , BUKH, Jens
IPC分类号： C12N7/00 , G01N33/576
CPC分类号： C12N7/00 , C12N2770/24221 , C12N2770/24234 , C12N2770/24252 , C12N2770/24271 , C12Q1/707 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to nucleic acid sequences that encode hepatitis C viruses (HCV) that are useful in the fundamental research of HCV as well as in the search of a vaccine against HCV. In particular the present invention relates to nucleic acid sequences that comprises HCVs which are capable of expressing said virus when transfected into cells and are capable of infectivity in vivo.
摘要翻译：本发明涉及编码丙型肝炎病毒（HCV）的核酸序列，其可用于HCV的基础研究以及针对HCV的疫苗的检索。特别地，本发明涉及包含HCV的核酸序列，其能够在转染入细胞时能够表达所述病毒并且能够在体内具有感染性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式